APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Atezolizumab

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Atezolizumab Market Outlook and Growth Opportunities 2026

Report ID 173967900423 December 2025190 pages

Choose your research edition.

Industry ResearchAtezolizumab Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Atezolizumab Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal Atezolizumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Atezolizumab Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Atezolizumab Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Atezolizumab market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Atezolizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Atezolizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Atezolizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Atezolizumab market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Atezolizumab market include Genentech (Roche). among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Atezolizumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Atezolizumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Atezolizumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Atezolizumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Atezolizumab Segment by Company

Genentech (Roche)

Atezolizumab Segment by Type

Use: Single Drug

Use: ChemOthersapy Combination

Atezolizumab Segment by Application

Advanced Triple-negative Breast Cancer

Head and Neck Cancer

Renal Cell Carcinoma

Urothelial Carcinoma

Hepatocellular Carcinoma (HCC)

Lung Cancer

Bladder Cancer

Others

Atezolizumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Atezolizumab status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Atezolizumab market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Atezolizumab significant trends, drivers, influence factors in global and regions.

6. To analyze Atezolizumab competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atezolizumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Atezolizumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atezolizumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Atezolizumab market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Atezolizumab industry.

Chapter 3: Detailed analysis of Atezolizumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Atezolizumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Atezolizumab in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Atezolizumab Industry Trends Table 2. Atezolizumab Industry Drivers Table 3. Atezolizumab Industry Opportunities and Challenges Table 4. Atezolizumab Industry Restraints Table 5. Global Atezolizumab Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Atezolizumab Revenue Share by Company (2021-2026) Table 7. Global Atezolizumab Sales Volume by Company (k units) & (2021-2026) Table 8. Global Atezolizumab Sales Volume Share by Company (2021-2026) Table 9. Global Atezolizumab Average Price (US$/unit) of Company (2021-2026) Table 10. Global Atezolizumab Company Ranking, (2024-2026) & (USD Million) Table 11. Global Atezolizumab Key Company Manufacturing Base & Headquarters Table 12. Global Atezolizumab Company, Product Type & Application Table 13. Global Atezolizumab Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Atezolizumab by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Use: Single Drug Table 18. Significant Companies of Use: ChemOthersapy Combination Table 19. Global Atezolizumab Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Atezolizumab Sales Volume by Type (2021-2026) & (k units) Table 21. Global Atezolizumab Sales Volume by Type (2027-2032) & (k units) Table 22. Global Atezolizumab Sales Volume Share by Type (2021-2026) Table 23. Global Atezolizumab Sales Volume Share by Type (2027-2032) Table 24. Global Atezolizumab Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Atezolizumab Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Atezolizumab Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Atezolizumab Sales Value Share by Type (2021-2026) Table 28. Global Atezolizumab Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Advanced Triple-negative Breast Cancer Table 30. Significant Companies of Head and Neck Cancer Table 31. Significant Companies of Renal Cell Carcinoma Table 32. Significant Companies of Urothelial Carcinoma Table 33. Significant Companies of Hepatocellular Carcinoma (HCC) Table 34. Significant Companies of Lung Cancer Table 35. Significant Companies of Bladder Cancer Table 36. Significant Companies of Others Table 37. Global Atezolizumab Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Atezolizumab Sales Volume by Application (2021-2026) & (k units) Table 39. Global Atezolizumab Sales Volume by Application (2027-2032) & (k units) Table 40. Global Atezolizumab Sales Volume Share by Application (2021-2026) Table 41. Global Atezolizumab Sales Volume Share by Application (2027-2032) Table 42. Global Atezolizumab Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Atezolizumab Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Atezolizumab Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Atezolizumab Sales Value Share by Application (2021-2026) Table 46. Global Atezolizumab Sales Value Share by Application (2027-2032) Table 47. Global Atezolizumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Atezolizumab Sales by Region (2021-2026) & (k units) Table 49. Global Atezolizumab Sales Market Share by Region (2021-2026) Table 50. Global Atezolizumab Sales by Region (2027-2032) & (k units) Table 51. Global Atezolizumab Sales Market Share by Region (2027-2032) Table 52. Global Atezolizumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Atezolizumab Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Atezolizumab Sales Value Share by Region (2021-2026) Table 55. Global Atezolizumab Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Atezolizumab Sales Value Share by Region (2027-2032) Table 57. Global Atezolizumab Market Average Price (US$/unit) by Region (2021-2026) Table 58. Global Atezolizumab Market Average Price (US$/unit) by Region (2027-2032) Table 59. Global Atezolizumab Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 60. Global Atezolizumab Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Atezolizumab Sales by Country (2021-2026) & (k units) Table 62. Global Atezolizumab Sales Market Share by Country (2021-2026) Table 63. Global Atezolizumab Sales by Country (2027-2032) & (k units) Table 64. Global Atezolizumab Sales Market Share by Country (2027-2032) Table 65. Global Atezolizumab Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Atezolizumab Sales Value Market Share by Country (2021-2026) Table 67. Global Atezolizumab Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Atezolizumab Sales Value Market Share by Country (2027-2032) Table 69. Genentech (Roche) Company Information Table 70. Genentech (Roche) Business Overview Table 71. Genentech (Roche) Atezolizumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Genentech (Roche) Atezolizumab Product Portfolio Table 73. Genentech (Roche) Recent Development Table 74. Key Raw Materials Table 75. Raw Materials Key Suppliers Table 76. Atezolizumab Distributors List Table 77. Atezolizumab Customers List Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Atezolizumab Product Image Figure 2. Global Atezolizumab Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Atezolizumab Sales Value (2021-2032) & (US$ Million) Figure 4. Global Atezolizumab Sales (2021-2032) & (k units) Figure 5. Global Atezolizumab Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Atezolizumab Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Use: Single Drug Image Figure 10. Use: ChemOthersapy Combination Image Figure 11. Global Atezolizumab Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Atezolizumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Atezolizumab Sales Volume Share by Type (2021-2032) Figure 14. Global Atezolizumab Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Atezolizumab Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Atezolizumab Sales Value Share by Type (2021-2032) Figure 17. Advanced Triple-negative Breast Cancer Image Figure 18. Head and Neck Cancer Image Figure 19. Renal Cell Carcinoma Image Figure 20. Urothelial Carcinoma Image Figure 21. Hepatocellular Carcinoma (HCC) Image Figure 22. Lung Cancer Image Figure 23. Bladder Cancer Image Figure 24. Others Image Figure 25. Global Atezolizumab Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Atezolizumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Atezolizumab Sales Volume Share by Application (2021-2032) Figure 28. Global Atezolizumab Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Atezolizumab Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Atezolizumab Sales Value Share by Application (2021-2032) Figure 31. Global Atezolizumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 32. Global Atezolizumab Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Atezolizumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Atezolizumab Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Atezolizumab Sales Value (2021-2032) & (US$ Million) Figure 36. North America Atezolizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Atezolizumab Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Atezolizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Atezolizumab Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Atezolizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Atezolizumab Sales Value (2021-2032) & (US$ Million) Figure 42. South America Atezolizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Atezolizumab Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Atezolizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Atezolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Atezolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Atezolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Atezolizumab Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Atezolizumab Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Use: Single Drug
  • Use: ChemOthersapy Combination
Applications
  • Advanced Triple-negative Breast Cancer
  • Head and Neck Cancer
  • Renal Cell Carcinoma
  • Urothelial Carcinoma
  • Hepatocellular Carcinoma (HCC)
  • Lung Cancer
  • Bladder Cancer
  • Others
Companies covered
  • Genentech (Roche)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Atezolizumab Sales Value (2021-2032)
  4. 1.2.2 Global Atezolizumab Sales Volume (2021-2032)
  5. 1.2.3 Global Atezolizumab Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Atezolizumab Market Dynamics
  1. 2.1 Atezolizumab Industry Trends
  2. 2.2 Atezolizumab Industry Drivers
  3. 2.3 Atezolizumab Industry Opportunities and Challenges
  4. 2.4 Atezolizumab Industry Restraints
3 Atezolizumab Market by Company
  1. 3.1 Global Atezolizumab Company Revenue Ranking in 2025
  2. 3.2 Global Atezolizumab Revenue by Company (2021-2026)
  3. 3.3 Global Atezolizumab Sales Volume by Company (2021-2026)
  4. 3.4 Global Atezolizumab Average Price by Company (2021-2026)
  5. 3.5 Global Atezolizumab Company Ranking (2024-2026)
  6. 3.6 Global Atezolizumab Company Manufacturing Base and Headquarters
  7. 3.7 Global Atezolizumab Company Product Type and Application
  8. 3.8 Global Atezolizumab Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Atezolizumab Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Atezolizumab Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Atezolizumab Market by Type
  1. 4.1 Atezolizumab Type Introduction
  2. 4.1.1 Use: Single Drug
  3. 4.1.2 Use: ChemOthersapy Combination
  4. 4.2 Global Atezolizumab Sales Volume by Type
  5. 4.2.1 Global Atezolizumab Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Atezolizumab Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Atezolizumab Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Atezolizumab Sales Value by Type
  9. 4.3.1 Global Atezolizumab Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Atezolizumab Sales Value by Type (2021-2032)
  11. 4.3.3 Global Atezolizumab Sales Value Share by Type (2021-2032)
5 Atezolizumab Market by Application
  1. 5.1 Atezolizumab Application Introduction
  2. 5.1.1 Advanced Triple-negative Breast Cancer
  3. 5.1.2 Head and Neck Cancer
  4. 5.1.3 Renal Cell Carcinoma
  5. 5.1.4 Urothelial Carcinoma
  6. 5.1.5 Hepatocellular Carcinoma (HCC)
  7. 5.1.6 Lung Cancer
  8. 5.1.7 Bladder Cancer
  9. 5.1.8 Others
  10. 5.2 Global Atezolizumab Sales Volume by Application
  11. 5.2.1 Global Atezolizumab Sales Volume by Application (2021 VS 2025 VS 2032)
  12. 5.2.2 Global Atezolizumab Sales Volume by Application (2021-2032)
  13. 5.2.3 Global Atezolizumab Sales Volume Share by Application (2021-2032)
  14. 5.3 Global Atezolizumab Sales Value by Application
  15. 5.3.1 Global Atezolizumab Sales Value by Application (2021 VS 2025 VS 2032)
  16. 5.3.2 Global Atezolizumab Sales Value by Application (2021-2032)
  17. 5.3.3 Global Atezolizumab Sales Value Share by Application (2021-2032)
6 Atezolizumab Regional Sales and Value Analysis
  1. 6.1 Global Atezolizumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Atezolizumab Sales by Region (2021-2032)
  3. 6.2.1 Global Atezolizumab Sales by Region: 2021-2026
  4. 6.2.2 Global Atezolizumab Sales by Region (2027-2032)
  5. 6.3 Global Atezolizumab Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Atezolizumab Sales Value by Region (2021-2032)
  7. 6.4.1 Global Atezolizumab Sales Value by Region: 2021-2026
  8. 6.4.2 Global Atezolizumab Sales Value by Region (2027-2032)
  9. 6.5 Global Atezolizumab Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Atezolizumab Sales Value (2021-2032)
  12. 6.6.2 North America Atezolizumab Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Atezolizumab Sales Value (2021-2032)
  15. 6.7.2 Europe Atezolizumab Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Atezolizumab Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Atezolizumab Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Atezolizumab Sales Value (2021-2032)
  21. 6.9.2 South America Atezolizumab Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Atezolizumab Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Atezolizumab Sales Value Share by Country, 2025 VS 2032
7 Atezolizumab Country-level Sales and Value Analysis
  1. 7.1 Global Atezolizumab Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Atezolizumab Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Atezolizumab Sales by Country (2021-2032)
  4. 7.3.1 Global Atezolizumab Sales by Country (2021-2026)
  5. 7.3.2 Global Atezolizumab Sales by Country (2027-2032)
  6. 7.4 Global Atezolizumab Sales Value by Country (2021-2032)
  7. 7.4.1 Global Atezolizumab Sales Value by Country (2021-2026)
  8. 7.4.2 Global Atezolizumab Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Atezolizumab Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Atezolizumab Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Atezolizumab Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Atezolizumab Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Atezolizumab Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Atezolizumab Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Atezolizumab Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Atezolizumab Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Atezolizumab Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Atezolizumab Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Atezolizumab Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Atezolizumab Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Atezolizumab Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Atezolizumab Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Atezolizumab Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Atezolizumab Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Atezolizumab Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Atezolizumab Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Atezolizumab Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Atezolizumab Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Atezolizumab Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Atezolizumab Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Atezolizumab Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Atezolizumab Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Atezolizumab Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Atezolizumab Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Atezolizumab Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Atezolizumab Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Atezolizumab Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Atezolizumab Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Atezolizumab Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Atezolizumab Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Atezolizumab Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Atezolizumab Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Atezolizumab Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Atezolizumab Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Atezolizumab Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Atezolizumab Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Atezolizumab Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Atezolizumab Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Atezolizumab Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Atezolizumab Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Atezolizumab Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Atezolizumab Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Atezolizumab Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Atezolizumab Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Atezolizumab Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Atezolizumab Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Atezolizumab Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Atezolizumab Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Atezolizumab Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Atezolizumab Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Atezolizumab Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Atezolizumab Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Atezolizumab Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Atezolizumab Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Atezolizumab Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Atezolizumab Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Atezolizumab Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Atezolizumab Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Atezolizumab Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Atezolizumab Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Atezolizumab Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Atezolizumab Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Atezolizumab Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Atezolizumab Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Atezolizumab Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Atezolizumab Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Atezolizumab Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Atezolizumab Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Atezolizumab Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Atezolizumab Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Atezolizumab Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Atezolizumab Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Atezolizumab Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Atezolizumab Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Atezolizumab Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Atezolizumab Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Atezolizumab Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Atezolizumab Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Atezolizumab Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Atezolizumab Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Atezolizumab Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Atezolizumab Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Genentech (Roche)
  2. 8.1.1 Genentech (Roche) Company Information
  3. 8.1.2 Genentech (Roche) Business Overview
  4. 8.1.3 Genentech (Roche) Atezolizumab Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Genentech (Roche) Atezolizumab Product Portfolio
  6. 8.1.5 Genentech (Roche) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Atezolizumab Value Chain Analysis
  2. 9.1.1 Atezolizumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Atezolizumab Sales Mode & Process
  6. 9.2 Atezolizumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Atezolizumab Distributors
  9. 9.2.3 Atezolizumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst